Skip to main content

Platform

AEO Website Research-grade Content Content Factory About Audits Rankings Pricing

Resources

Knowledge Base Research FAQ
Audit
OverviewHow to ImproveScore BreakdownSite PagesGuides
nevakar.com

nevakar.com

Weak AI visibility with 14 of 48 criteria passing. Biggest gap: llms.txt file.

Biotech & PharmaceuticalsPharmaceuticals
29/100
16 since v2
F
Citation Avg
Coherence gate active - score capped at 60
Answer Readiness
~40% weight
4/10
Content Structure
~25% weight
2/10
Trust & Authority
~15% weight
1/10
Technical Foundation
~10% weight
4/10
AI Discovery
~10% weight
2/10

Verdict

Critical AEO gaps at 29/100 - nevakar.com is largely invisible to AI engines. Key strengths include Duplicate Content Blocks, Page Speed: Load Blockers, and Page Speed: Page Size. Priority gaps: llms.txt File, Schema.org Structured Data, and Comprehensive FAQ Section. Topic coherence is moderate at 5/10, capping the score at 60. Tighter topical focus would lift this ceiling.

How to Improve

Current
29/100
Projected
78/100
42Total Fixes
14Quick Wins
~96hEst. Effort
Quick Wins
Create /llms.txt fileFix HTML structure and meta tagsConfigure robots.txt for AI crawlersLink orphan pages into site navigationAdd structured tables and listsAdd direct answer paragraphsAdd ai.txt and content licensingEnhance author and expert schemaImprove query-answer alignmentAdd visible date signalsReduce extraction frictionEliminate cross-page duplicate contentReduce render-blocking resourcesReduce document weight
Fix HTML structure and meta tags
high|low
Create /llms.txt file
critical|low
Add llms-full.txt with extended content
medium|low
Configure robots.txt for AI crawlers
high|trivial
Reduce render-blocking resources
high|low
Reduce document weight
high|low
Add internationalization signals
critical|medium
Improve server response efficiency
medium|low
Create complete sitemap.xml
low|low

Top Opportunities10

Publish original research, statistics, case studies, or proprietary data that AI engines can cite. Unique data points make your content a primary source rather than a derivative one.

Expand articles to 1000+ words with structured H2/H3 sections, comparison tables, and expert analysis. Thin content (under 300 words) is rarely cited by AI engines. Deep, well-structured articles demonstrate expertise.

Ensure blog content consistently covers your core expertise areas rather than scattering across unrelated topics. AI engines build authority models - a site about "Medicare coverage" that also publishes about humidifiers and groceries dilutes its topical authority.

Write concise, standalone answer paragraphs (2-3 sentences) immediately after question headings. These "snippet-ready" paragraphs are ideal for AI engine citations.

Use HTML tables for comparison data and ordered/unordered lists for features, steps, and specifications. Structured data formats are directly extractable by AI engines for answers.

Add specific numbers, percentages, statistics, and data points throughout your content. Fact-dense content gives AI engines concrete data to cite rather than vague claims.

Add more proper nouns throughout content - named sources, organizations, tools, studies, and locations. Cited text averages 20.6% proper nouns; most sites fall well below 15%.

Add question-based headings (H2/H3) throughout your content. Use "What is...", "How does...", "Why should..." patterns that match how users query AI assistants.

Write self-contained definition sentences and single-claim statements that AI engines can quote directly. Avoid pronouns like "this" or "that" at the start of answer paragraphs.

Add Organization schema with consistent name, address, phone (NAP). Include sameAs links to social profiles and authoritative directories to strengthen entity recognition.

Fix It With AI46

Your competitors are already optimizing for AI

Every day without action is traffic your site loses to AI-ready competitors. We fix that.

Fix My Score

Site Pages

nevakar.com/vyluma-announces-positive-results-from-phase-...D41
VYLUMA ANNOUNCES POSITIVE RESULTS FROM PHASE 3 CHAMP STUDY OF NVK002 FOR TREATMENT OF MYOPIA PROGRESSION IN CHILDREN | Nevakar Inc.
nevakar.com/vyluma-announces-acceptance-of-drug-applicati...F39
Vyluma announces acceptance of drug application for NVK002 by China’s National Medical Products Administration (NMPA) | Nevakar Inc.
nevakar.com/newsD42
News | Nevakar Inc.
nevakar.com/nevakar-announces-first-subject-dosed-in-its-...F37
Nevakar Announces First Subject Dosed in its Phase 3 Clinical Trial of NVK002 for the Treatment of Myopia in Children | Nevakar Inc.
Changes since v2Last audited 46 days ago
45
29
-16
View full comparison →
Add Original Data & Case StudiesIncrease Content DepthFocus Content on Core TopicsAdd Direct Answer ParagraphsAdd Structured Tables & ListsIncrease Fact & Data DensityIncrease Entity DensityRestructure Content as Q&AImprove Citation-Ready WritingStrengthen Entity Authority (NAP)

Improve Your Score

Guides for the criteria with the most room for improvement

Related Questions

Browse all FAQs →

Want us to improve your score?

We build citation-ready content that AI engines choose as the answer.

Let's Talk